PROCEEDS AGREEMENTProceeds Agreement • May 24th, 2023 • Baker Bros. Advisors Lp • Pharmaceutical preparations
WHEREAS, the Agent, in his capacity as a director of ACADIA Pharmaceuticals Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 12,500 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • July 26th, 2023 • Virginia
This PROCEEDS AGREEMENT, dated [November 9], 2023 (this "Proceeds Agreement"), is among the VIRGINIA PUBLIC SCHOOL AUTHORITY, a public body corporate and instrumentality of the Commonwealth of Virginia ("VPSA"), and the
PROCEEDS AGREEMENTProceeds Agreement • February 28th, 2019 • Baker Bros. Advisors Lp • Services-medical laboratories • New York
WHEREAS, the Agent, in his capacity as a director of Genomic Health, Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 8,250 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • March 15th, 2023 • Baker Bros. Advisors Lp • Services-commercial physical & biological research
WHEREAS, the Agent, in his capacity as a director of Incyte Corporation (the “Company”), received non-transferable options (the “Options”) to purchase 20,000 shares of the Company common stock (the “Stock”) according to the below Schedule A;
Worksheet 1 Participation & Proceeds AgreementProceeds Agreement • January 4th, 2017
We, the signatories below, agree that between 16 January 2017 and 26 March 2017 our participation in the Channel Islands Student Business Challenge will be equal and potential proceeds from the Challenge will be distributed equally.
PROCEEDS AGREEMENTProceeds Agreement • January 30th, 2017 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances) • New York
AGREEMENT dated as of January 26, 2017 by and between Baker Bros. Advisors LP (the “Management Company”) and Michael Goller (the “Agent”).
PROCEEDS AGREEMENTProceeds Agreement • May 3rd, 2018 • Baker Bros. Advisors Lp • Services-commercial physical & biological research • New York
WHEREAS, the Agent, in his capacity as a director of Incyte Corporation (the “Company”), received non-transferable options (the “Options”) to purchase 20,000 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • May 19th, 2016 • Baker Julian • Services-medical laboratories • New York
WHEREAS, the Agent, in his capacity as a director of Genomic Health, Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 8,250 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • March 17th, 2016 • Baker Julian • Services-commercial physical & biological research • New York
WHEREAS, the Agent, in his capacity as a director of Incyte Corporation (the “Company”), received non-transferable options (the “Options”) to purchase 20,000 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • February 16th, 2016 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances) • New York
AGREEMENT dated as of February 11, 2016 by and between Baker Bros. Advisors LP (the “Management Company”) and Michael Goller (the “Agent”).
PROCEEDS AGREEMENTProceeds Agreement • June 1st, 2017 • Baker Bros. Advisors Lp • Services-medical laboratories • New York
WHEREAS, the Agent, in his capacity as a director of Genomic Health, Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 8,250 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • April 28th, 2017 • Baker Bros. Advisors Lp • Services-commercial physical & biological research • New York
WHEREAS, the Agent, in his capacity as a director of Incyte Corporation (the “Company”), received non-transferable options (the “Options”) to purchase 20,000 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • May 9th, 2024 • Baker Bros. Advisors Lp • Services-commercial physical & biological research
WHEREAS, the Agent, in his capacity as a director of Incyte Corporation (the “Company”), received non-transferable options (the “Options”) to purchase 15,000 shares of the Company common stock (the “Stock”) according to the below Schedule A;
1 EXHIBIT 10.10 PROCEEDS AGREEMENT THIS AGREEMENT dated as of April 5, 1999 is made by and among PHILIP SERVICES CORP. ("PSC"), PHILIP SERVICES (DELAWARE), INC. ("PSI" and, together with PSC, the "Borrowers") and each of the direct and indirect...Proceeds Agreement • April 29th, 1999 • Philip Services Corp • Sanitary services • Ontario
1 EXHIBIT 10.6 PROCEEDS AGREEMENT The undersigned parties to the Merger Agreement and Plan of Reorganization dated as of May 17, 2000 (the "Merger Agreement") hereby agree as follows (any capitalized terms not defined herein having the meanings given...Proceeds Agreement • May 23rd, 2000 • Professional Transportation Group LTD Inc • Arrangement of transportation of freight & cargo
PROCEEDS AGREEMENTProceeds Agreement • April 29th, 2020 • Baker Bros. Advisors Lp • Services-commercial physical & biological research • New York
WHEREAS, the Agent, in his capacity as a director of Incyte Corporation (the “Company”), received non-transferable options (the “Options”) to purchase 20,000 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • June 26th, 2018 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances) • New York
WHEREAS, the Agent, in his capacity as a director of DBV Technologies S.A. (the “Company”), received non-transferable warrants (the “Warrants”) to purchase 7,000 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • March 12th, 2018 • Baker Bros. Advisors Lp • Services-medical laboratories • New York
WHEREAS, the Agent, in his capacity as a director of Genomic Health, Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 8,250 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • January 10th, 2024 • Virginia
This PROCEEDS AGREEMENT, dated [May 14], 2024 (this "Proceeds Agreement"), is among the VIRGINIA PUBLIC SCHOOL AUTHORITY, a public body corporate and instrumentality of the Commonwealth of Virginia ("VPSA"), and the counties and
EXHIBIT E PROCEEDS AGREEMENT [HSBC Bank USA Letterhead] December 14, 2005Proceeds Agreement • December 20th, 2005 • Royal Gold Inc • Mineral royalty traders
This is to advise you that HSBC Bank USA (“HSBC”) has continued a credit facility in favor of Royal Gold, Inc. (“Royal Gold”) pursuant to the Amended and Restated Loan Agreement dated as of December 14, 2005 between HSBC and Royal Gold (the “Loan Agreement”), which amends and restates in its entirety the Loan Agreement dated as of December 18, 2000 between HSBC and Royal Gold. The Loan Agreement is secured by various collateral security arrangements, including: (1) a lien and security interest in favor of HSBC on Royal Gold’s share of all mineral production (“Production”) from the GSR#1 Royalty, the GSR#3 Royalty and the NVR#1 Royalty, each on the Pipeline/South Pipeline Mining Complex in Lander County, Nevada (the “Project”), (2) a security interest in all proceeds of such Production (“Proceeds”), and (3) a security interest in all accounts of Royal Gold, whether metals or monetary, and credit balances therein, with Johnson Matthey Inc. (“Accounts”).
